

Chapter 13
Task Forces and Special Projects

13.1. Task Forces

13.1.1. Task Force on Ethics (TF-E)

Membership

Name	Position	Country	Term	Time in Office
A. Gronowski	Chair	US	1 st	2015 01 - 2017 12
E.Y. Arcellana Nuqui	Member	PH	1 st	2014 04 - 2016 12
T. Higgins	Member	CA	1 st	2014 04 - 2016 12
A. Newman	Member	NL	Extra Term	2015 01 - 2015 12
K. Okhan Akin	Member	TR	1 st	2014 04 - 2016 12
C. Sekadde-Kigonde	Member	KE	1 st	2014 04 - 2016 12
D. Bruns	Consultant	US		
J. Jonsson	Consultant	IS		

Aims:

- To increase awareness among Laboratory Medicine Professionals of ethical issues
- To encourage the practice of Laboratory Medicine to the highest ethical standards
- To develop position papers on appropriate ethics policies issues
- To provide a voice for Laboratory Medicine on ethics policies
- To link Laboratory Medicine, ethics and the public interest.

Objectives:

- Recognising that IFCC is formed by representatives from Clinical Chemistry and Laboratory Medicine in more than 70 countries plus more than 30 corporate members, it is unlikely that position papers will have the complete agreement of all of our members. They are position papers and should not be put to a vote. The objective is to produce a statement with widespread support from the members of the Federation
- A secondary objective is to ensure that each paper is published in professional journal(s) and that it is also made available to the general public.

Background:

During the term 1997-1999, the EB of the IFCC accepted the principle of establishing an Ethics Committee. It was identified that the greatest need was not for a Committee that would look inwardly at personal and professional ethics or codes of behaviour, since these can best be dealt with at the level of the individual society or country. During the past 20 years there has been an increasing number of pre-symptomatic tests that can be offered to the community. Some of the challenges have been in laboratory organisation and testing but these are minor compared to broader issues affecting those targeted for screening and the general community. DNA testing combined with newer genetic and biochemical techniques raise significant issues of community awareness, education, informed consent and pre- and post-test counselling. The genetic information stored and used must also have safeguards that ensure there are no stigmatisation and discrimination issues. In various parts of the world individual professional organisations have raised awareness of these issues among their members and have produced documents addressing some of the key issues. In general, the Laboratory Medicine community has not provided organised discussion in which the members can actively participate. There has been even less effort at the international level to create a collective voice for Laboratory Medicine. Laboratory Medicine organisations have a goal and responsibility to advance the interest of their members but the IFCC strategic vision also clearly states that the ultimate goal is to benefit the health and well-being of the patients and communities we serve. This test of our professional responsibility demands that we do not simply perform tests and use technology uncritically. We cannot be isolated from the impact of our work on society.

List of Addresses:

Prof. Ann GRONOWSKI

Department of Pathology & Immunology
Washington University School of Medicine
660 South Euclid Avenue, Box 8118
St. Louis, Missouri 63110
USA
E-mail: gronowski@wustl.edu

Dr. Elizabeth Y. ARCELLANA NUQUI

Consultant Director, Clinical Chemistry
Department of Laboratory Medicine
The Medical City Ortigas Avenue
Pasig City
Philippines
E-mail: bethayan@gmail.com

Dr. Trefor HIGGINS

Director of Clinical Chemistry
DynaLIFEDx
Canada
E-mail: trefor.higgins@dynamlifedx.com

Dr. Anthony NEWMAN

Publisher, Biochemistry, Applied
Biochemistry and Clinical Chemistry
portfolio, Life Sciences Dept., Elsevier,
Radarweg 29, 1043 NX Amsterdam
The Netherlands
E-mail: a.newman@elsevier.com

Prof. Dr. Kadir OKHAN AKIN

Medical Park Ankara
Hastanesi Kent Koop Mah. 1868. Sok.
No. 15 Batikent
Ankara
Turkey
E-mail: dr.okhanakin@gmail.com

Prof. Christine SEKADDE-KIGONDU

Department of Human Pathology
Unit of Clinical Chemistry
School of Medicine
College of Health Sciences
University of Nairobi
Kenya
E-mail: ckigondu@aar.co.ke

13.1.2. Task Force on Pediatric Laboratory Medicine (TF-PLM)

Membership

Name	Position	Country	Term	Time in Office
M. Metz	Chair	AU	1 st	2015 01 - 2017 12
T. Lang	Vice-Chair	UK	1 st	2015 01 - 2017 12
V. L. Grey	Past-Chair	CA	1 st	2015 01 - 2017 12
S.M. Geaghan	Member	US	2 nd	2014 01 - 2016 12
M. Hersberger	Member	CH	1 st	2015 01 - 2017 12
T.P. Loh	Member	SG	1 st	2015 01 - 2017 12
M. Turzyniecka	Member	ZA	1 st	2015 01 - 2017 12
P.M. Jones	Advisor	US		
K. Kohse	Advisor	DE		

Improving diagnosis and management of patients from birth to adolescence:

The purpose of this Task Force is to develop procedures and processes to improve the diagnosis and management of patients from birth to adolescence.

This Task Force will:

- Coordinate activities worldwide directed towards the establishment of reference intervals for laboratory test results in pediatric patients of all age groups
- Form a sound support basis for the continuation of the International Congresses of Pediatric Laboratory Medicine which have been very successful over the past 25 years
- Create a worldwide network of scientists working in laboratories specialized in Pediatric Medicine.

Why Pediatric laboratory medicine?

Children are not simply small adults - this holds especially true when they become patients. Pediatric patients comprise a group with special problems, also with regards to the results of laboratory investigations.

Local and regional activities exist in which an exchange of ideas and concepts for the role of the laboratory in the care of children's health take place, but in general, these activities are not linked to each other. In spite of a variety of activities in the past years, reference intervals for laboratory test results are often not very well defined for the pediatric population, a situation which is even worse in adolescent medicine.

The subject of the Task Force is obviously relevant to large numbers of people - a substantial proportion of our patients are children. Especially in pediatric patients, the role of the laboratory is crucial for diagnosis and follow-up, e.g., in metabolic disorders or genetically determined diseases.

Activities of the Task Force will include:

- Coordination, promotion and development of existing IFCC SD research activities associated with reference intervals. Existing regional groups within IFCC, e.g., the Nordic States (Denmark, Sweden, Norway, Finland and Iceland) are currently engaged in the development of Pediatric Reference values. By close interaction with this group and the IFCC SD, the Task Force will expand these activities to other regions of the world
- Integration and eventually merging of the Board of the International Association of Pediatric Medicine into the Task Force and continue to motivate the then former members of this Association worldwide to support the activities of the Task Force
- Establishment of a concept for the next International Congresses of Pediatric Medicine. As the preferred setting, the Congress will be held in conjunction with an IFCC meeting or a meeting taking place under the auspices of IFCC
- Regularly publish reports on the progress of the Task Force's activities and other relevant articles in the field of Pediatric Laboratory Medicine in the IFCC Journal

List of Addresses:

Dr. Michael P METZ

BS, MD, FAAP, MAACB, FRCPA
Consultant Chemical Pathologist
SAPath at The Women's & Children's
Hospital
72 King William Road,
North Adelaide, South Australia 5067
Australia
E-mail: michael.metz@health.sa.gov.au

Prof. Vijay L. GREY

Department of Pathology and
Molecular Medicine
McMaster University
Medical Centre, Rm 3N26F
1200 Main St W
Hamilton, ON L8N 3Z5
Canada
E-mail: greyv@mcmaster.ca

Dr. Tim LANG

Clinical Biochemistry Department
University Hospital of North Durham
North Road
Durham, DH1 5TW
United Kingdom
E-mail: Tim.Lang@cddft.nhs.uk

Dr. Sharon MARKHAM GEAGHAN

Stanford University School of Medicine
Department of Pathology
300 Pasteur Drive
Palo Alto CA 94304
USA
E-Mail: sgeag@stanford.edu

Dr. Martin HERSBERGER
 Professor of Clinical Chemistry
 Head of the Division of Clinical Chemistry
 and Biochemistry
 University Children's Hospital Zurich
 Steinwiesstrasse 75
 8032 Zurich
 Switzerland
 E-mail: martin.hersberger@kispi.uzh.ch

Dr. Tze Ping LOH
 Department of Laboratory Medicine
 National University Hospital
 5 Lower Kent Ridge Road
 119074 Singapore
 E-mail: tploh@hotmail.com

Dr. Magdalena TURZYNiecka
 Department of Chemical Pathology
 University of Kwazulu-Natal
 Mazisi Kunene Road,
 Glenwood
 Durban
 South Africa
 E-mail: mturzyniecka@yahoo.com

Prof. Patricia M. JONES
 Department of Pathology, Children's
 Medical Center
 1935 Motor Street 75235
 Dallas
 USA
 E-mail: patti.jones@childrens.com

Prof. Klaus P. KOHSE
 Institute for Laboratory Diagnostics and
 Microbiology, Klinikum Oldenburg
 10, Dr.-Eden-Street
 D-26133
 Oldenburg
 Germany
 E-mail:
 kohse.klaus@klinikum-oldenburg.de

13.1.3. Task Force on Pharmacogenetics (Integrated Project) - (TF-PG)

Membership

Name	Position	Country	Term	Time in Office
R. Van Schaik	Chair	NL	Extra-Term	2015 01 - 2015 12
M. Linder	Member	US	1 st	2015 01 - 2017 12
M. Neumaier	Member	DE	Extra-Term	2015 01 - 2015 12
H. Guchelaar	Consultant	NL		
M. Pirmohamed	Consultant	UK		

Aim:

The aim of the Task Force is to facilitate integration of pharmacogenetic testing into routine diagnostics at the appropriate quality standards.

Objectives:

1. Obtain information on the potential clinical utility of specific pharmacogenetic tests
2. Obtain information on current perception of genetic variants to be tested
3. Obtain information on clinical recommendations based on the pharmacogenetic test results from the clinical disciplines involved.
4. Discuss and weigh the information obtained.
5. Prepare guiding documents, with participation of the clinical disciplines involved, per drug/gene combination for pharmacogenetic testing, addressing who to test, how to test, how to interpret and how to report.
6. Identify Pharmacogenetics Expert Labs, in collaboration with the Committee for Molecular Diagnostics.

Delivery:

7. Network of pharmacogenetic experts from in- and outside Clinical Chemistry.
8. Network of specific contact persons within the relevant clinical disciplines.
9. Guidance documents: TPMT testing and 6-mercaptopurine/azathioprine, CYP2C19 testing and clopidogrel, CYP2D6 testing and tamoxifen.
10. Presentation of ongoing work of IFCC TF-PG in presentations and posters at different conferences.

Accountability:

The Task Force is directly responsible to the EB through the President.

List of Addresses:

Dr. Ron VAN SCHAik
 Department of Clinical Chemistry
 Erasmus University Medical Centre
 Gavendijkwal 230,
 's Gravendijkwal 230
 3015 CE Rotterdam
 The Netherlands
 Tel: +31 10 70 33119
 E-mail: r.vanschaik@erasmusmc.nl

Prof. Henk-Jan GUCHELAAR
 Dept. Clinical Pharmacy and Toxicology
 Leiden University Medical Centre
 P.O. Box 9600
 2300 RC Leiden
 The Netherlands
 Tel: +31 71 526 2790
 E-Mail: H.J.Guchelaar@lumc.nl

Professor Mark W. LINDER
 Department of Pathology and Laboratory
 Medicine
 University of Louisville, School of Medicine
 Louisville, Kentucky 40202
 USA
 E-mail: mark.linder@louisville.edu

Prof. Munir PIRMOHAMED
 Dept. Pharmacology
 The University of Liverpool
 Ashton Street
 Liverpool, L69 3GE
 United Kingdom
 Tel: +44 151 794 5549
 E-Mail: munirp@liverpool.ac.uk

Prof. Michael NEUMAier
 Medical Faculty Mannheim
 University of Heidelberg
 University Hospital Mannheim
 Theodor-Kutzer-Ufer 1-3
 D-68167 Mannheim
 Germany
 Tel: +49 621 383 2222
 E-Mail: michael.neumaier@medma.uni-heidelberg.de

13.1.4. Task Force on Chronic Kidney Disease (Integrated Project) - (TF-CKD)

Membership

Name	Position	Country	Term	Time in Office
G. Jones	Chair	AU	2 nd	2011 01 - 2013 12
J. Coresh	Member	US	2 nd	2014 01 - 2016 12
J. Delanghe	Member	BE	2 nd	2014 01 - 2016 12
E. Lamb	Member	UK	2 nd	2014 01 - 2016 12
A. Narva	Member	US	2 nd	2014 01 - 2016 12
M. Panteghini	Member	IT	2 nd	2014 01 - 2016 12
D. Seccombe	Member	CA	2 nd	2014 01 - 2016 12
F. Alcantara	WASPALM Nominee	BR		
J. H. Eckfeldt	WASPALM Nominee	US		

Aim:

To promote, support and co-ordinate international activities related to laboratory testing in Chronic Kidney Disease (CKD).

Objectives:

1. Obtain information on the current state of co-ordinated national and international activity in the area of pathology testing in CKD.
2. Assess current best practice in CKD-related testing.
3. Assess best practice for implementation of best practice for CKD-related testing.
4. Provide assistance where required for member organisations and others in planning and implementing CKD testing policies and guidelines.
5. Identify other relevant areas of laboratory related issues in CKD.

Delivery:

1. A report on the current status of guidelines on CKD pathology testing.
2. A review of the items covered in CKD pathology testing guidelines.
3. A review of best practice processes for implementing change in CKD-related pathology testing.
4. An assessment of areas of likely relevant future activity in CKD testing.

Accountability:

The Task Force is accountable to the President through the Chair.

List of Addresses:

Dr. Graham JONES

Department of Chemical Pathology
St Vincent's Hospital
Sydney - Australia
Tel: +61 2 8382 9160
E-mail: Graham.Jones@svha.org.au

Dr. Joris DELANGHE

Department of Clinical Chemistry
University Hospital of Ghent
B-9000 Ghent - Belgium
Tel: +61 9 332 2956
E-Mail: joris.delanghe@ugent.be

Prof. Josef CORESH

Department of Biostatistics & Medicine
Johns Hopkins University
2024 E. Monument, Suite 2-630
Baltimore, MD 21287 - USA
Tel: +1 410 955 0495
E-mail: coresh@jhu.edu

Dr. Edmund LAMB

Department of Clinical Biochemistry
Kent & Canterbury Hospital
Canterbury
Kent CT1 3NG - United Kingdom
Tel: 01227 766877 X74736
E-mail: elamb@nhs.net

Dr. Andrew S NARVA

Director, National Kidney Disease
Education Program
National Institutes of Health
Two Democracy Plaza, Room 644
6707 Democracy Blvd, MSC-5458
Bethesda, MD 20892-5458
United States
Tel : +1 301 594 8864
E-Mail: narvaa@nidk.nih.gov

Prof. David W SECCOMBE

Department of Pathology and
Laboratory Medicine
University of British Columbia
Vancouver BC V6R 4N6
Canada
Tel : +1 604 222 3907
E-Mail: dseccombe@ceqal.com

Prof. Mauro PANTEGHINI

Dipartimento di Scienze Cliniche
'Luigi Sacco'
Università degli Studi di Milano
Via G.B. Grassi, 74
20157 Milano - Italy
Tel: +39 02 3904 2806
E-Mail: mauro.panteghini@unimi.it

WASPALM Nominees

Dr. Flavio F. ALCANTARA

Medico Assistente
Seção de Biologia Molecular
Divisão de Laboratório Central DLC
Hospital das Clínicas FM USP - Brazil
Tel.: +55 (11) 30697275
Cel.: +55 (11) 8181 0185
Cel.: +55 (13) 9610 9303
E-Mail: flavio.alcantara@hc.fm.usp.br

Dr. John H. ECKFELDT

Dept. Lab. Med. and Pathology, MMC 609
Univ. of MN, Room 763-1 Mayo Bldg.
420 Delaware Street, S.E.
Minneapolis, MN 55455
USA
Tel: +1 612-626-3176
E-Mail: eckfe001@umn.edu

13.1.6. IFCC Task Force for Young Scientists (TF-YS)

Membership

Name	Position	Country	Term	Time in Office
P. Kumar Dabla	Chair	IN	1 st	2014 04 - 2016 12
G. Boursier	Member	FR	1 st	2014 04 - 2016 12
B. Imperiale	Member	AR	1 st	2013 03 - 2015 12
D. Li	Member	US	1 st	2013 03 - 2015 12
O. Popoola	Member	NG	1 st	2013 03 - 2015 12
M. Savkovic	Member	SRB	1 st	2013 03 - 2015 12
D. Gruson	Consultant	BE		

Aim:

The aim of TF-YS is to ensure that young scientists make a significant and growing contribution to the activities of IFCC and to the promotion of laboratory medicine at the centre of healthcare.

Objectives:

- To identify young scientists amongst IFCC Full and Corporate Members
- To use modern information technology to establish formal and informal networks to facilitate the communication between young scientists who are involved in laboratory medicine

- To link with national society young scientist initiatives
- To encourage young scientists to share experience of laboratory medicine and other healthcare practice around the world
- To disseminate and promote innovation and high quality scientific and clinical practice standards
- To facilitate opportunities for young scientists to train in modern, state of the art laboratory practice
- To enable young scientists to participate in scientific, clinical and educational meetings and other learning sessions
- To encourage young scientists to participate in national and international programmes to promote the essential contribution of laboratory medicine to healthcare
- To make young scientists aware of the existence and role of IFCC and to encourage their participation in IFCC activities
- To assure the future of IFCC through the identification of young scientists who may develop into future experts capable of leading IFCC Divisions, Committees and Working Groups and becoming IFCC Officers

Delivery:

- For the purposes of definition a young scientist is a medical or science graduate working or training in laboratory medicine. He/she will normally be aged less than 40 yrs at the time of appointment to work with TF-YS. The term of office of any young scientist involved with TF-YS is three years with renewal for a maximum of one further three year term of office.
- TF-YS will comprise a Chair and, normally, a maximum of four other core members. Core membership of TF-YS will ensure geographical representation and linkage to national societies that have experience of working with young scientists. TF-YS will also have an extensive number of corresponding members. All IFCC Full Members and Corporate Members will be invited to nominate young scientists to serve as core or corresponding members of TF-YS. Membership of TF-YS will be confirmed by the IFCC Executive Board on the recommendation of the TF-YS Chair.
- TF-YS will communicate mainly through modern electronic and social networking media. Communication will include all core and corresponding members of TF-YS and may develop into other networks as agreed by TF-YS.
- Core members of TF-YS will be invited to attend one Task Force meeting each year with expenses paid for by IFCC. Any corresponding member of TF-YS will be able to attend this annual meeting although IFCC is unable to provide travel or accommodation costs for corresponding members.
- TF-YS may organise regular workshops for young scientists within the framework of existing IFCC international or regional meetings. With the permission from the organisers TF-YS may also hold occasional workshops within national society or specialist society meetings. No expenses will be paid by IFCC for attendance at these workshops.
- TF-YS will be able to communicate with and request support from other IFCC functional units.

Accountability:

The TF-YS will report directly to the IFCC Executive Board. A nominated member of the Executive Board will act as a liaison person for TF-YS. The TF-YS will prepare an update report for each meeting of the Executive Board and may contact the Board, through the designated liaison person, at other times. Any additional finance raised by TF-YS will be accounted for through normal IFCC accounting procedures and will be subject to financial audit.

List of addresses:

Dr. Pradeep KUMAR DABLA

Assistant Professor
Department of Biochemistry
G.B.Pant Institute of Postgraduate
Medical Education & Research
(GIPMER)
Delhi-110002 - India
Tel.: +91 9868524455
E-mail: pradeep_dabla@yahoo.com

Dr. Guilaine BOURSIER

Department of Clinical Biochemistry
CHU Montpellier
France
E-mail: guilaineboursier@yahoo.fr

Dr. Belen IMPERIALE

Microbiology Unit
Dr. Cetrangolo Hospital
Laboratory of TB Control Program of
Buenos Aires Province
Argentina
E-mail: belen_imperiale@yahoo.com

Dr. Danni LI

Assistant Professor
Director of Clinical Chemistry
University of Minnesota Medical Center
Fairview
Department of Lab Medicine and
Pathology, MMC 609
420 Delaware Street SE
Mayo Building D250-1
Minneapolis, MN 55455
USA
E-mail: dannili@umn.edu

Dr. Omolara Olutosin POPOOLA

P.M.B 5116, Chemical Pathology
Department
University College Hospital
Ibadan - Nigeria
Tel.: +2348056738867
E-mail: larrylabs@yahoo.co.uk

Dr. Miljan SAVKOVIC

Center for Medical Biochemistry
Clinical Center of Serbia
Pasterova 2
11000 Belgrade
Serbia
E-mail: miljansavkovic@yahoo.com

13.1.7. Task Force on Clinical Applications of Cardiac Bio-Markers (TF-CB)

Membership

Name	Position	Country	Term	Time in Office
J. Ordoñez-Llanos	Chair	ES	2 nd	2014 01 - 2016 12
F. Apple	Member	US	2 nd	2014 01 - 2016 12
M.HM. Chan	Member	HK	2 nd	2014 01 - 2016 12
P. Collinson	Member	UK	2 nd	2014 01 - 2016 12
J.E. Hollander	Member	US	2 nd	2014 01 - 2016 12
A. Jaffe	Member	US	2 nd	2014 01 - 2016 12
B. Lindhal	Member	SE	2 nd	2014 01 - 2016 12
M. Möckel	Member	DE	2 nd	2014 01 - 2016 12
M. Plebani	Member	IT	2 nd	2014 01 - 2016 12
M. Than	Member	NZ	2 nd	2014 01 - 2016 12

Terms of Reference:

- Education; Established and novel cardiac biomarkers
- Biochemistry of cardiac biomarkers
- Clinical use of cardiac biomarkers: risk stratification, diagnostics, therapy
- Laboratory issues on cardiac biomarkers: 99th percentiles, delta values, biological variation, quality specifications of assays.

Current Projects:

- Development of educational materials about high-sensitive troponin assay use.

List of addresses:

Dr. Jordi ORDÓÑEZ-LLANOS

Senior Consultant, Biochemistry Dept.
Hospital de Sant Pau
Professor of Clinical Biochemistry
Universitat Autònoma
Barcelona
Spain
Tel.: +34 935537359
E-mail: JOrdonez@santpau.cat

Dr. Fred APPLE

Hennepin County Medical Center
Professor, Laboratory Medicine and
Pathology University of Minnesota
School of Medicine
701 Park Avenue
Clinical Labs P4
Minneapolis MN 55415
USA
Tel.: +1 612 873 3324
E-mail: apple004@umn.edu

Dr. MHM CHAN

Consultant Chemical Pathologist
Department of Chemical Pathology
The Chinese University of Hong Kong
Prince of Wales Hospital
Shatin, NT, Hong Kong
E-mail: hmchan@ha.org.hk

Dr. Paul O. COLLINSON

Department of Chemical Pathology
2nd Floor Jenner Wing
St George's Hospital
Blackshaw Road
London SW17 0QT UK
Tel.: +44 208 725 5934
E-mail: Paul.Collinson@stgeorges.nhs.uk

Dr. Judd HOLLANDER

Professor, Clinical Research Director
Department of Emergency Medicine
Hospital of University of Pennsylvania
Philadelphia, PA 19104-4283
USA
Tel.: +1 215 662-2767
E-mail: Judd.Hollander@verizon.net

Dr. Allan JAFFE

Cardiovascular Division, Gonda 5
Mayo Clinic
200 First Street SW
Rochester - MN 55905
USA
Tel.: +1 507 284 1648
E-mail: jaffe.allan@mayo.edu

Dr. Bertil LINDHAL

Uppsala Clinical Research Center
University Hospital
SE 75185 Uppsala
Sweden
Tel.: +46 18 6119595
E-mail: bertil.lindahl@ucr.uu.se

Dr. Martin MÖCKEL

Charité Campus Virchow
Department of Medicine and Cardiology
Augustenburger Platz 1
13353 Berlin
Germany
E-mail: martin.moeckel@charite.de

Prof. Mario PLEBANI

Department of Laboratory Medicine
University-Hospital of Padova
Italy
Tel.: +39 049 8212792
E-mail: mario.plebani@unipd.it

Dr. Martin THAN

Emergency Department
21 Taylor's Mistake Road
8081 Christchurch
New Zealand
Tel. +64 3 326 7599
E-mail: martinthan@xtra.co.nz

13.1.8. Task Force on Point of Care Testing (TF-POCT)

Membership

Name	Position	Country	Term	Time in Office
R. Tirimacco	Chair	AU	2 nd	2015 01 - 2017 12
A.I. Khan	Member	CA	2 nd	2015 03 - 2017 12
G.J. Kost	Member	US	2 nd	2015 01 - 2017 12
P. Pernet	Member	FR	2 nd	2015 01 - 2017 12
T.J. Allison	Corp. Rep./Siemens	US	2 nd	2015 01 - 2017 12
A. Skurup	Corp. Rep./Radiometer	DK	2 nd	2015 01 - 2017 12

Terms of Reference:

- To promote quality in the use, performance, interpretation and reporting of POCT across the full spectrum of clinical chemistry and laboratory medicine
- To create a forum for high level discussion on a wide range of POCT related topics
- To provide international leadership for developing the clinical practice of POCT in Laboratory Medicine.

Objectives:

- Creation of a communication network for specialists who are expert in POCT. To include other POCT specialist groups; expert individuals in IFCC Full, Affiliate and Corporate Members; regulatory agencies and users of POCT
- Definition, implementation, evaluation and reporting of a range of defined POCT projects. To include projects that address quality in POCT performance, the appropriate clinical use of POCT, connectivity and the cost effectiveness of POCT. Projects should complement rather than duplicate projects being undertaken by other POCT specialists
- Preparation of educational support material for those using or considering the use of POCT
- Creation of a library of publications that document the clinical effectiveness of POCT and the impact on clinical outcomes. To include clinical chemistry, haematology, microbiology and other disciplines of laboratory medicine, as appropriate

List of addresses:

Rosy TIRIMACCO

Network Operations & Research
Manager iCCnet
Country Health SA
Local Health Network Inc.
Mail box 28, Level 3B
Mark Oliphant Building, Science Park
Bedford Park
South Australia 5042
Australia
Tel.: +61-(0)8-8201 7842
Mobile: +61 0412 749 418
Fax: +61-(0)8-8201 7850
E-mail: Rosy.Tirimacco@health.sa.gov.au

Dr. Adil Irfan KHAN

Assistant Professor of Pathology
Director, Point of Care Testing
Department of Pathology and
Laboratory Medicine
Temple University School of Medicine
100 E. Lehigh Avenue
Philadelphia, PA 19125 - USA
Telephone: +1 (215) 707-0965 (office)
Fax: +1 (215) 707-0966
E-mail: adil.khan@temple.edu

Dr. Gerald Joseph KOST

Director, Point-of-Care Testing Center for
Teaching and Research (POCT•CTR)
Professor, Pathology and Laboratory
Medicine
Faculty, Biomedical Engineering &
Comparative Pathology

School of Medicine
3455 Tupper Hall
University of California
Davis, CA, USA 95616
E-mail: gjkost@ucdavis.edu

Dr. Pascal PERNET

Praticien Hospitalier
Responsable Médical d'Unité
(Laboratoire de Biologie d'Urgence)
Service de Biochimie A/Pôle de Biologie
Médicale et Pathologie
Hôpitaux Universitaires Est Parisien
(AP-HP)
site Saint-Antoine
184 rue du fg St-Antoine
75571 Paris Cedex 12 - France
Tél : +33 01 49 28 22 20
Fax : +33 01 49 28 20 77
E-mail: pascal.pernet@sat.aphp.fr

Mr. Trevor J. ALLISON

Director, Research & Development
Siemens Healthcare Diagnostics
Sudbury, Suffolk, UK, CO10 2XQ
Tel: +44 (0) 1787 242600
Mobile: +44 (0) 7921 243235
E-mail: trevor.allison@siemens.com

Ms Anne SKURUP

Clinical and Scientific Affairs Manager
Blood Gas
Radiometer Medical
Åkandevvej 21
2700 Brønshøj - Denmark
Tel.: + 45 3827 3348
Mobile + 45 2014 4074
E-mail: anne.skurup@radiometer.dk

Working Group on “How should Glucose Meters be Evaluated for Critical Care - (WG-GMECC)” – under the responsibility of the TF-POCT

Membership

Name	Position	Country	Term	Time in Office
C. Bowman	Chair	US	1 st	2013 03 - 2015 12
E. Bigot-Corbel	Member	FR	1 st	2014 04 - 2016 12
S. Cunningham	Member	IE	1 st	2013 03 - 2015 12
E. Guillen Barua	Member	PY	1 st	2013 03 - 2015 12
P. Luppa	Member	DE	1 st	2013 03 - 2015 12
T. Malati	Member	IN	1 st	2013 03 - 2015 12
D. Sacks	Member	US	1 st	2013 03 - 2015 12
R. Slingerland	Member	NL	1 st	2014 04 - 2016 12
B. Solnica	Member	PL	1 st	2013 03 - 2015 12
P. St.Louis	Member	CA	1 st	2013 03 - 2015 12
R. White	Member	AU	1 st	2013 03 - 2015 12
F. Vanstapel	Member	BE	1 st	2013 03 - 2015 12
E. Ntrivalas	Corp. Rep./Nova Biomedical	UK	1 st	2012 03 - 2014 12
M. Mulder	Corp. Rep./Roche	DE	1 st	2012 03 - 2014 12
D. Bruns	Advisor			
B. Clarke	Advisor			

Terms of Reference:

1. Evaluate the clinical practice of using blood glucose meters for critically ill patients.
2. Determine the requirements a glucose meter need to full fill in order to be used for critically ill patients.
3. Propose what internal- and external quality control systems that should be present.
4. Evaluate which, if any, of the present instruments in the market fulfil these criteria.
5. Provide recommendations for training and competency of users in critical care areas.
6. Ensure recommendations align with other stakeholders.

List of addresses:

Dr. Cynthia BOWMAN

Enzo Clinical Labs
60 Executive Blvd
Farmingdale, NY 11735
USA
Tel.: +1 631-755-5500 ext. 422
E-mail: cynthia.f.bowman@gmail.com

13.1.11. Task Force on Proficiency Testing (TF-PT)

Membership

Name	Position	Country	Term	Time in Office
A. Haliassos	Chair	GR	1 st	2014 04 - 2016 12
B. Aslan	Member	CA	1 st	2014 04 - 2016 12
A. Carobene	Member	IT	1 st	2014 04 - 2016 12
A. Perret-Liaudet	Member	FR	1 st	2014 04 - 2016 12
C. Weykamp	Member	NL	1 st	2014 04 - 2016 12
J. Dai	Corp. Rep./Siemens	US	1 st	2014 04 - 2016 12
M. Rottmann	Corp. Rep./Roche	DE	1 st	2014 04 - 2016 12

Aims:

- To facilitate the introduction of international proficiency testing schemes for uncommon but clinically important measurands.
- To use the information to select measurands that may be suitable for method harmonization as a means to improving patient outcomes.

Objectives:

- To establish a small group of clinical and scientific experts who represent both suppliers and users of ‘uncommon but clinically important’ laboratory medicine methods.
- To agree a definition of an ‘uncommon but clinically important’ measurand and the body of evidence that is required to meet that definition.
- To write a specification for operating an international proficiency testing scheme.
- To survey IFCC Members and IFCC functional units to receive suggestions for ‘uncommon but clinically important’ measurands.
- To prioritize the suggestions received and to assess the potential for international proficiency testing and the likely support of manufacturers of available methods.
- To establish the availability of proficiency testing schemes for the identified measurands. Where proficiency testing schemes exist to assess their potential for expansion at an international level.
- In the absence of suitable proficiency testing schemes to invite bids to provide measurand specific proficiency testing in accordance with the agreed specification.
- To recommend to the Executive Board proficiency testing schemes that may be set up under the auspices of IFCC.
- To monitor performance in IFCC supported proficiency testing schemes and to support the preparation of scientific publications at appropriate points in time.
- To use performance data from IFCC supported proficiency testing schemes to propose measurands for harmonization in line with www.harmonization.net.

Background:

The role of Proficiency Testing schemes (External Quality Assessment programmes)

is of prime importance to the analytical quality, to the standardisation of the methods and to the harmonisation of the results. However, there is a lack of interest from the commercial providers of such schemes, either for the more new and complex tests and for the very old and simple measurands that involve a new calibration curve, because of the very subtle problems induced at the interpretation of the statistical results of their, already well-established and running, schemes.

A multidisciplinary effort had assigned to the new Task Force on Proficiency Testing (TF-PT) involved in the analysis and the exploration of the above mentioned of Proficiency Testing issues. This could lead to the establishment of specialised schemes under the auspices of the IFCC and may enhance harmonisation of laboratory results.

Achievements during 2013-2014:

The TF-PT had its initial meeting in Istanbul in June 2014 and agreed a way of working. Further informal meetings were held with C-AQ; during the annual meeting of AACCC (July 2014 in Chicago) and with the board of EQALM in Toulouse at the end of October 2014.

Plans for 2015-2017:

The central project of the TF-PT will be the creation of an online database - web application accessible via web browsers but also via specific applications for the major mobile platforms with much more functionalities and ease of use. The roots of this database will be the analytes (tests, measurands) that will be filed with all possible synonyms (one of them will be the "official" as proposed from the Nomenclature, Properties and Units (C-NPU) committee of the SD) as also as the methods (assays, instruments, reagents etc) also with all possible synonyms.

Registered users can indicate which analytes require introduction of a PT scheme.

Another part of the DB, maintained with the cooperation of C-AQ and of EQALM, will be the PT providers section containing all their contact information, their programmes with the analytes, frequencies, type of statistics, commutability of control materials, their accreditation or certification status etc.

The database will be accessible for consultation freely to all visitors of IFCC site, but only registered users will have modification privileges. The registration of users will be by invitation from the NR and the CM, via the IFCC secretariat and from the EQALM. The registered users will have the possibility to invite more members via the application. In summary, the database will interactively link our colleagues, final users of the tests, with PT providers, IVD manufacturers, accreditation bodies etc. and will facilitate the search for a PT scheme for "rare" esoteric or new analytes, or the introduction of a new one if needed.

Cooperation:

1. The Task Force will work in close association with the IFCC Committee for Analytical Quality (C-AQ)
2. The Task Force will work in close association with the IFCC Committee Traceability in Laboratory Medicine (C-TLM)
3. The Task Force will work in close association with the IFCC Committee Nomenclature, Properties and Units (C-NPU)
4. The Task Force will liaise with the EQALM and other relevant international providers of proficiency testing in laboratory medicine.

List of addresses:

Dr. Alexander HALIASSOS

ESEAP - Greek Proficiency Testing Scheme
for Clinical Laboratories
GSCC-CB
47 Alopekis Str
GR-106 76 Athens
Greece
E-mail: haliassos@moleculardiagnosics.gr

Dr. Berna ASLAN

Associate Director, External Quality Assessment
QMP-LS/IQMH
393 University Avenue, Unit 1500
Toronto ON M5G 1E6
Canada
E-mail: aslan_berna@hotmail.com

Dr. Anna CAROBENE

Standardization Laboratory in Clinical Chemistry
San Raffaele Hospital
Via Olgettina 60
20132 Milano
Italy
E-mail: carobene.anna@hsr.it

Dr. Armand PERRET-LIAUDET

Directeur laboratoire des maladies à Prion et d'Alzheimer
Centre de Biologie et pathologie Est
Hôpitaux de Lyon
59, Bd Pinel 69500 Bron
France
E-mail: armand.perret-liaudet@chu-lyon.fr

Dr. Cas W. WEYKAMP

Queen Beatrix Hospital
Clinical Chemistry
Beatrixpark 1
7101 BN Winterswijk
The Netherlands
E-mail: c.w.weycamp@skbwinterswijk.nl

Dr. Jian DAI

Siemens Healthcare Diagnostics Inc.
Newark DE 19702
USA
E-mail: j.dai@siemens.com

Dr. Michael ROTTMANN

Director, assay development
Endocrinology
Thyroid, Sepsis, RA
Roche Diagnostics GmbH
Roche Professional Diagnostics
Nonnenwald, 2
82372 Penzberg
Germany
E-mail: michael.rottmann@roche.com

13.1.14. Task Force on “IFCC-CLMA” Project on Leadership (TF IFCC-CLMA)

Membership

Name	Position	Country	Term	Time in Office
L. Kricka	Chair	US	1 st	2014 04 - 2016 12
E. Frank	Member	IN	1 st	2014 04 - 2016 12
B. Gouget	Member	FR	1 st	2014 04 - 2016 12
J. Smith	Member	UK	1 st	2014 04 - 2016 12
P. Labbe	CLMA Member	US	1 st	2014 04 - 2016 12
M. Dumond	CLMA Member	US	1 st	2014 04 - 2016 12
R. Forsman	CLMA Member	US	1 st	2014 04 - 2016 12
C. Orner	CLMA Member	US	1 st	2014 04 - 2016 12

Aim:

To assess unmet leadership development needs of laboratory professionals and recommend mechanisms for resolution.

Objectives:

1. Determine a model for assessing and comparing a country’s capabilities to improve laboratory leadership competencies and the prioritization it attaches to that activity.
2. Verify the utility of the model through its application to a sampling of developed, newly industrialized and developing countries.
3. Using the model, identify unmet needs in the countries sampled.
4. Determine possible strategies for resolving unmet needs.

Background:

IFCC includes a committee (C-CLM) whose mandate is to produce monographs and/or handbooks on basic clinical laboratory management and to offer courses, seminars, workshops and expertise to IFCC members. The committee’s initial focus will be on addressing the needs of developing countries. CLMA is an international organization focused solely on the non-technical needs of laboratory management and has developed a Body of Knowledge identifying the domains of management for the laboratory. The opportunity for partnership could serve to create a more comprehensive offering in a shorter time and at a lower cost serving the goals of both organizations and the needs of their respective members.

Action Plan:

1. Establish a Task Force with representations from IFCC and interested IFCC affiliates. CLMA will do the same.
2. Create a survey that identifies country-specific approaches to defining and measuring leadership competencies, the in-country resources to develop these competencies, and the efforts to do so. Seek IFCC affiliate support for dissemination. Consider CLMA’s Body of Knowledge for Medical Laboratory Management and other models of leadership competencies in constructing the survey. Complete the survey and prepare preliminary findings.
3. Based on responses to the survey, determine a model that can be used to describe leadership development and leadership development resources in countries regardless of their socioeconomic development. Leadership factors will include such items as the level of financial accountability, responsibility for personnel evaluation, the level of decision authority, etc. Development resources will include the educational system, the availability of on-the-job training, professional associations, government, etc.
4. Identify approximately 10 countries to be studied using the developed model which

should include ~3 developed countries, ~3 newly industrialized countries and ~4 developing countries.

5. Work with participating countries to assess the suitability, applicability and likely acceptability of the leadership development model.
6. Following analysis of the data, prepare a joint report to the IFCC and CLMA executive boards with findings and specific recommendations on the need for future work. The work should be completed no later than June 2016.

Users or beneficiaries of the product resulting from the project:

1. IFCC and all of its Members and functional units
2. CLMA and all its chapters and members
3. Professionals in management/leadership roles within a medical laboratory
4. Educators in the field of laboratory medicine
5. Patients and the general public.

List of addresses:

Prof. Larry J KRICKA

Department of Pathology & Laboratory
Medicine
University of Pennsylvania Medical Center
3400 Spruce Street Philadelphia,
PA 19104
USA
E-mail: kricka@mail.med.upenn.edu

Dr. Bernard GOUGET

Fédération Hospitalière de France
Univ. Paris V 1 bis Rue Cabanis
75993 Paris Cedex 14
France
Tel: +33 1 440 68444/8470
E-mail: b.gouget@fhf.fr

Dr. Elizabeth A FRANK

c/o Bio-Chem Diagnostic Laboratory
No.4 Railway Co-Operative Bank
Sheshadri Iyer Road
570 021 Mysore
India
Tel: +91 821 2432321
E-mail: anet21frank@yahoo.com

Ms. Janet SMITH

Clinical Biochemistry
University Hospital Birmingham
NHS Trust
Birmingham B29 6JD
UK
E-mail: janmsmith@talk21.com

CLMA Members:

Dr. Paul LABBE

Paul.R.Labbe@questdiagnostics.com

Dr. Mark DUMOND

Mark.Dumond2@healthtrustpg.com

Dr. Rodney FORSMAN

forsman.rodney@mayo.edu

Dr. Carla ORNER

carla.ornier@hearttoheart.org

13.2. IFCC Professional Exchange Programme (PEP)

IFCC offers a small number of scholarships each year to facilitate professional exchange programmes for young scientists. The purpose of professional exchange programmes is to:

- Promote international co-operation between laboratories
- Facilitate the exchange of young laboratory scientists between IFCC Member societies
- Share high level scientific or management skills
- Introduce new or improved scientific or management skills to the applicant's laboratory.

Applicants for an IFCC professional exchange programme will:

- be a member of an IFCC Full Member or Affiliate Member national society
- be aged under 40 years at the time of the exchange programme
- have a specific project to complete in a designated host laboratory
- not have received funding from IFCC for other PEPs.

Applications must have the support of both partner laboratories.

Duration of exchanges: 3 months maximum.

Successful applicants will be entitled to receive economy return travel expenses from his/her home base to the host laboratory and a subsistence allowance for a maximum of three months.

At the completion of a professional exchange programme the successful applicant is required to:

- Write a short report of his/her experience for publication in IFCC News.
- Where appropriate, submit a scientific paper for publication in the electronic journal of IFCC.

These exchange programmes are open for laboratories in all countries where an IFCC member society is active.

For complete details of these programmes and how to apply for participation, please visit the IFCC website at: <http://www.ifcc.org/ifcc-education-division/pep-professional-exchange-programme/>.

IFCC has developed two categories of professional exchange programme:

- Professional Scientific Exchange Programme (PSEP)
- Professional Management Exchange Programme (PMEP).

13.2.1. Professional Scientific Exchange Programme (PSEP)

The purpose of a PSEP is to exchange or develop high level scientific information or skills.

Applications for a PSEP may come from any IFCC Full Member or Affiliate Member national society.

Examples of suitable PSEP projects include (but are not restricted to):

- Conduct of a collaborative research project between base and host laboratories;
- Use of a method or technique not available in the base laboratory in order to complete a research project;
- Learning a new method or technique in the host laboratory which will be introduced into the base laboratory after the PSEP is complete;
- Completion of a collaborative evidence-based scientific project such as the preparation of a systematic review;

Scientific publications resulting from this exchange programme have to acknowledge IFCC's support.

13.2.2. Professional Management Exchange Programme (PMEP)

The purpose of a PMEPE is to develop appropriate quality management skills in order to improve the performance and quality of service offered to patients by the base laboratory.

Applications for a Professional Management Exchange Programme (PMEPE) may only come from IFCC Full Member or Affiliate Member national societies that are in countries where quality management and/or laboratory accreditation are at an early stage of development.

Examples of PMEPE include:

- Acquiring skills to introduce effective internal quality control;
- Acquiring skills to introduce an external quality assurance scheme to a country;
- Acquiring skills to introduce quality management to the base laboratory;
- Preparation to enable the base laboratory to apply for laboratory accreditation in line with ISO Standard 15189.

The host laboratory for a PMEPE will normally be in the same IFCC Region as the applicant.

13.3. IFCC Travel Scholarships

IFCC-Roche travel scholarships are available to allow young scientists from developing countries to participate in relevant international scientific congresses and conferences. Applicants should be working in a developing country member of IFCC and should be less than 40y of age on 1 January of the year in which the congress or conference occurs. Priority will be given to applicants who are submitting an abstract to the meeting.

IFCC-Roche travel scholarships may be used for any relevant international scientific congress or conference. Each year IFCC promotes the scheme and lists some IFCC meetings that do qualify, but this list is not exclusive. It is a condition of the scheme that the congress or conference should take place in a country other than that in which the applicant works.

The IFCC-Roche travel scholarship will provide funding towards the cost of economy travel and accommodation. IFCC will seek to ensure that scholarship recipients receive free registration for the congress or conference that they attend.

Applicants will be required to complete the application form that can be obtained from the IFCC Office (ifcc@ifcc.org). The completed application should be submitted, together with supporting information, to the IFCC Office.

IFCC acknowledges the generous sponsorship from Roche Diagnostics GmbH for this scheme.

Additionally, IFCC is able to offer two other travel scholarships that follow the same rules as specified above:

- Jocelyn Hicks travel scholarship
- Past Presidents travel scholarships.